Development of antiemetic therapy in cancer patientsHERRSTEDT, J.Acta oncologica (Stockholm). 1995, Vol 34, Num 5, pp 637-640, issn 0284-186XConference Paper

Antiemetic research : a look to the futureHERRSTEDT, J.Supportive care in cancer. 1998, Vol 6, Num 1, pp 8-12, issn 0941-4355Conference Paper

New perspectives in antiemetic treatmentHERRSTEDT, J.Supportive care in cancer. 1996, Vol 4, Num 6, pp 416-419, issn 0941-4355Article

Chemotherapy-induced nausea and vomiting : ESMO Clinical Recommendations for prophylaxisHERRSTEDT, J; ROILA, F.Annals of oncology. 2008, Vol 19, issn 0923-7534, ii110-ii112, SUP2Article

Increased myelosuppression during cytostatic treatment and pleural effusion in patients with small cell lung cancerHERRSTEDT, J; CLEMENTSEN, P; HANSEN, O. P et al.European journal of cancer. Part A. 1992, Vol 28, Num 6-7, pp 1070-1073Article

Interaction of the antiemetic metopimazine and anticancer agents with brain dopamine D₂, 5-hydroxytryptamine₃, histamine H₁, muscarine cholinergic and α₁-adrenergic receptorsHERRSTEDT, J; HYTTEL, J; PEDERSEN, J et al.Cancer chemotherapy and pharmacology. 1993, Vol 33, Num 1, pp 53-56, issn 0344-5704Article

Randomized, double-blind comparison of granisetron versus granisetron plus prednisolone as antiemetic prophylaxis during multiple-day cisplatin-based chemotherapyHANDBERG, J; WESSEL, V; LARSEN, L et al.Supportive care in cancer. 1998, Vol 6, Num 1, pp 63-67, issn 0941-4355Article

High-performance liquid chromatographic method with fluorescence detection for the simultaneous determination of metopimazine and its acid metabolite in serumANGELO, H. R; HERRSTEDT, J; JØRGENSEN, M et al.Journal of chromatography. 1989, Vol 496, Num 2, pp 472-477, issn 0021-9673Article

Bone health in cancer patients: ESMO Clinical Practice GuidelinesCOLEMAN, R; BODY, J. J; AAPRO, M et al.Annals of oncology. 2014, Vol 25, issn 0923-7534, iii124-iii137, SUP3Article

The Multinational Association for Supportive Care in Cancer risk index : A Multinational scoring system for identifying low-risk febrile neutropenic cancer patientsKLASTERSKY, J; PAESMANS, M; TALCOTT, J et al.Journal of clinical oncology. 2000, Vol 18, Num 16, pp 3038-3051, issn 0732-183XArticle

Antiemetic efficacy of combination therapy with granisetron plus prednisolone plus the dopamine D₂ antagonist metopimazine during multiple cycles of moderately emetogenic chemotherapy in patients refractory to previous antiemetic therapySIGSGAARD, T; HERRSTEDT, J; CHRISTENSEN, P et al.Supportive care in cancer. 2000, Vol 8, Num 3, pp 233-237, issn 0941-4355Conference Paper

Bioavailability of the antiemetic metopimazine given as a microenemaHERRSTEDT, J; JØRGENSEN, M; ANGELO, H. R et al.British journal of clinical pharmacology. 1996, Vol 41, Num 6, pp 613-615, issn 0306-5251Article

A dose escalating study of topotecan preceding cisplatin in previously untreated patients with small-cell lung cancerSORENSEN, M; JENSEN, P. B; HERRSTEDT, J et al.Annals of oncology. 2000, Vol 11, Num 7, pp 829-835, issn 0923-7534Article

Clinical and methodological issues in antiemetic therapy : a worldwide survey of experts' opinionsBALLATORI, E; ROILA, F; HESKETH, P et al.Supportive care in cancer. 1997, Vol 5, Num 4, pp 269-273, issn 0941-4355Article

Randomized, double-blind comparison of ondansetron versus ondansetron plus metopimazine as antiemetic prophylaxis during platinum-based chemotherapy in patients with cancerHERRSTEDT, J; SIGSGAARD, T; HANDBERG, J et al.Journal of clinical oncology. 1997, Vol 15, Num 4, pp 1690-1696, issn 0732-183XArticle

Sex hormone levels in postmenopausal women with advanced metastatic breast cancer treated with CGS 169 49 ASVENSTRUP, B; HERRSTEDT, J; BRÜNNER, N et al.European journal of cancer. Part A. 1994, Vol 30, Num 9, pp 1254-1258Article

Early recognition of malnutrition and cachexia in the cancer patient: a position paper of a European School of Oncology Task ForceAAPRO, M; ARENDS, J; STRASSER, F et al.Annals of oncology. 2014, Vol 25, Num 8, pp 1492-1499, issn 0923-7534, 8 p.Article

Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapySIGSGAARD, T; HERRSTEDT, J; ANDERSEN, L. J et al.British journal of cancer. 1999, Vol 80, Num 3-4, pp 412-418, issn 0007-0920Article

The value of yearly chest X-ray in patients with stage I breast cancerVESTERGAARD, A; HERRSTEDT, J; THOMSEN, H. S et al.European journal of cancer & clinical oncology. 1989, Vol 25, Num 4, pp 687-689, issn 0277-5379, 3 p.Article

Addition of the oral NK₁ antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapyDE WIT, R; HERRSTEDT, J; RAPOPORT, B et al.Journal of clinical oncology. 2003, Vol 21, Num 22, pp 4105-4111, issn 0732-183X, 7 p.Article

Dose-finding study of oral metopimazineHERRSTEDT, J; SIGSGAARD, T; ANGELO, H. R et al.Supportive care in cancer. 1997, Vol 5, Num 1, pp 38-43, issn 0941-4355Article

Toremifene and tamoxifen in advanced breast cancer : a double-blind cross-over trialSTENBYGAARD, L. E; HERRSTEDT, J; THOMSEN, J. F et al.Breast cancer research and treatment. 1993, Vol 25, Num 1, pp 57-63, issn 0167-6806Article

Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortalityJØRGENSEN, T. L; HALLAS, J; FRIIS, S et al.British journal of cancer. 2012, Vol 106, Num 7, pp 1353-1360, issn 0007-0920, 8 p.Article

Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conferenceROILA, F; HERRSTEDT, J; GRUNBERG, S. M et al.Annals of oncology. 2010, Vol 21, issn 0923-7534, v232-v243, SUP5Article

The oral NK₁ antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trialsDE WIT, R; HERRSTEDT, J; RAPOPORT, B et al.European journal of cancer (1990). 2004, Vol 40, Num 3, pp 403-410, issn 0959-8049, 8 p.Article